Despite Humira’s Challenges, AbbVie’s Execution Makes It A Buy

Summary:

  • AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth.
  • The company has a solid track record of increasing dividends and offers an attractive current yield.
  • Despite the loss of exclusivity on its blockbuster drug Humira, AbbVie has other growth opportunities and a capable management team.

Adalimumab Prescription

Hailshadow

Introduction

The healthcare sector has always been fascinating to me. It combines innovative approaches that can achieve a significant premium for its products with essential products. Therefore, these companies tend to be more resilient to economic uncertainties. One such company is AbbVie (


Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *